- Home
- NRIX vs UWMC Comparison
NRIX vs UWMC Comparison
Compare NRIX & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- UWMC
- Stock Information
- Founded
- NRIX 2009
- UWMC 1986
- Country
- NRIX United States
- UWMC United States
- Employees
- NRIX N/A
- UWMC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- NRIX Health Care
- UWMC Finance
- Exchange
- NRIX Nasdaq
- UWMC Nasdaq
- Market Cap
- NRIX 766.0M
- UWMC 876.2M
- IPO Year
- NRIX 2020
- UWMC N/A
- Fundamental
- Price
- NRIX $10.56
- UWMC $5.45
- Analyst Decision
- NRIX Strong Buy
- UWMC Hold
- Analyst Count
- NRIX 15
- UWMC 7
- Target Price
- NRIX $29.13
- UWMC $5.54
- AVG Volume (30 Days)
- NRIX 678.5K
- UWMC 9.2M
- Earning Date
- NRIX 10-10-2025
- UWMC 08-07-2025
- Dividend Yield
- NRIX N/A
- UWMC 7.29%
- EPS Growth
- NRIX N/A
- UWMC 112.84
- EPS
- NRIX N/A
- UWMC 0.07
- Revenue
- NRIX $88,381,000.00
- UWMC $2,622,828,000.00
- Revenue This Year
- NRIX $71.51
- UWMC $16.65
- Revenue Next Year
- NRIX N/A
- UWMC $16.18
- P/E Ratio
- NRIX N/A
- UWMC $82.75
- Revenue Growth
- NRIX 41.86
- UWMC 13.45
- 52 Week Low
- NRIX $8.18
- UWMC $3.80
- 52 Week High
- NRIX $29.56
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- UWMC 71.05
- Support Level
- NRIX $9.44
- UWMC $4.43
- Resistance Level
- NRIX $10.98
- UWMC $5.64
- Average True Range (ATR)
- NRIX 0.57
- UWMC 0.24
- MACD
- NRIX -0.08
- UWMC 0.13
- Stochastic Oscillator
- NRIX 38.75
- UWMC 84.99
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.